Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences is reportedly in talks to raise new capital at a valuation of $20B-$30B, potentially doubling or tripling its previous valuation. This development is significant in the biotech and startup spaces. Engineers may want to keep an eye on this company's progress as it could have implications for the field of biotechnology. No immediate action is required, but staying informed about this development could be beneficial.